Ingmar Gorman, Ph.D., a clinical psychologist and co-founder of a psychedelic education company, shares insights on the FDA's controversial rejection of MDMA-assisted therapy for PTSD. He explains the intricacies surrounding the accusations faced by the therapy and the challenges in studying adverse experiences. Gorman also critiques the impact of public scrutiny and emphasizes the need for balanced media narratives. He calls for deeper journalist research to move beyond sensationalism and highlights the importance of acknowledging the human stories in psychedelic therapy.